Responses
Case Report
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
Compose a Response to This Article
Other responses
No responses have been published for this article.